Investigating the effects of mTOR inhibitors on aging in older adults
RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An exploratory PK/PD study of mTOR inhibition in older human subjects
This study is looking at how two medications, Rapamycin and Everolimus, might help older adults aged 65 to 90 stay healthier as they age, by figuring out the best doses to take and how these drugs affect their bodies.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10982162 on NIH RePORTER |
What this research studies
This research explores how medications that inhibit the mTOR pathway, specifically Rapamycin and Everolimus, may help slow down aging-related health issues in older adults. The study will involve healthy individuals aged 65 to 90, who will participate in a short-term trial to determine the safest and most effective dosing strategies for these drugs. Researchers will measure how the body processes these medications and their effects on biological markers associated with aging. The goal is to find optimal dosing that could lead to improved health and longevity for older adults.
Who could benefit from this research
Good fit: Ideal candidates for this research are healthy older adults aged 65 to 90 who are interested in potential interventions for age-related health issues.
Not a fit: Patients who are not healthy or have significant underlying health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments that enhance health and longevity in older adults.
How similar studies have performed: Previous studies in animal models have shown promising results with mTOR inhibitors, but this research aims to establish their effects in humans, making it a novel exploration.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Kraig, Ellen — University of Texas Hlth Science Center
- Study coordinator: Kraig, Ellen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.